Pharming Group (NASDAQ:PHAR) Sees Large Increase in Short Interest

Pharming Group (NASDAQ:PHAR) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 5,800 shares, a growth of 107.1% from the February 28th total of 2,800 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 6,700 shares, the days-to-cover ratio is currently 0.9 days.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on PHAR shares. Oppenheimer boosted their price objective on Pharming Group from $30.00 to $39.00 and gave the company an “outperform” rating in a research report on Friday, March 14th. HC Wainwright restated a “buy” rating and set a $37.00 price target on shares of Pharming Group in a research report on Thursday, March 20th. Finally, Jefferies Financial Group started coverage on shares of Pharming Group in a research report on Monday, December 9th. They issued a “buy” rating and a $14.00 price objective on the stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in Pharming Group (NASDAQ:PHAR) by 16.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 47,997 shares of the company’s stock after buying an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 at the end of the most recent reporting period. 0.03% of the stock is currently owned by institutional investors.

Pharming Group Stock Performance

Pharming Group stock traded down $0.27 during mid-day trading on Friday, hitting $8.38. 5,632 shares of the company’s stock traded hands, compared to its average volume of 6,202. Pharming Group has a one year low of $6.65 and a one year high of $11.30. The company has a market cap of $569.83 million, a PE ratio of -32.22 and a beta of -0.10. The firm has a 50 day moving average price of $8.80 and a 200 day moving average price of $8.66. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.02). The company had revenue of $92.70 million during the quarter, compared to analyst estimates of $76.67 million. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. On average, equities analysts forecast that Pharming Group will post -0.2 EPS for the current year.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.